Cell Line Development Market Size, Share & Trends Report

Cell Line Development Market Size, Share & Trends Analysis Report by Product, By Source (Mammalian, Non-Mammalian), By Type of Cells, By Application, By Technology, And Segment Forecasts, 2012 - 2022

  • Published Date: Feb, 2018
  • Base Year for Estimate: 2014
  • Report ID: 978-1-68038-481-9
  • Format: Electronic (PDF)
  • Historical Data: 2012 - 2014
  • Number of Pages: 154

Market Segmentation

  • Global Cell Line Development Product Outlook (Revenue, USD Million, 2012 - 2022)
    • Reagents and media
    • Equipment
      • Incubators
      • Centrifuges
      • Bioreactors
      • Storage equipment
      • Microscopes
    • Accessories and consumables
  • Global Cell Line Development Source Outlook (Revenue, USD Million, 2012 - 2022)
    • Mammalian cell line
    • Non-mammalian cell line
      • Insects
      • Amphibians
  • Global Cell Line Development Type Of Cell Lines Outlook (Revenue, USD Million, 2012 - 2022)
    • Recombinant cell lines
    • Hybridomas
    • Continuous cell lines
    • Primary cell lines
  • Global Cell Line Development Application Outlook (Revenue, USD Million, 2012 - 2022)
    • Bioproduction
    • Drug discovery
    • Toxicity testing
    • Tissue engineering
    • Research
  • Global Cell Line Development Regional Outlook (Revenue, USD Million, 2012 - 2022)
    • North America
      • North America Product Outlook (Revenue, USD Million, 2012 - 2022)
        • Reagents and media
        • Equipment
          • Incubators
          • Centrifuges
          • Bioreactors
          • Storage equipment
          • Microscopes
        • Accessories and consumables
      • North America Source Outlook (Revenue, USD Million, 2012 - 2022)
        • Mammalian
        • Non-mammalian 
          • Insects
          • Amphibians
      • North America Type of Cell Line Outlook (Revenue, USD Million, 2012 - 2022)
        • Recombinant cell lines
        • Hybridomas
        • Continuous cell lines
        • Primary cell lines
      • North America Application Outlook (Revenue, USD Million, 2012 - 2022)
        • Bioproduction
        • Drug discovery
        • Toxicity resting
        • Tissue engineering
        • Research
      • The U.S
        • The U.S. Product Outlook (Revenue, USD Million, 2012 - 2022)
          • Reagents and media
          • Equipment
            • Incubators
            • Centrifuges
            • Bioreactors
            • Storage equipment
            • Microscopes
          • Accessories and consumables
        • The U.S. Source Outlook (Revenue, USD Million, 2012 - 2022)
          • Mammalian
          • Non-mammalian 
            • Insects
            • Amphibians
        • The U.S. Type of Cell Line Outlook (Revenue, USD Million, 2012 - 2022)
          • Recombinant cell lines
          • Hybridomas
          • Continuous cell lines
          • Primary cell lines
        • The U.S. Application Outlook (Revenue, USD Million, 2012 - 2022)
          • Bioproduction
          • Drug discovery
          • Toxicity resting
          • Tissue engineering
          • Research
      • Canada
        • Canada Product Outlook (Revenue, USD Million, 2012 - 2022)
          • Reagents and media
          • Equipment
            • Incubators
            • Centrifuges
            • Bioreactors
            • Storage equipment
            • Microscopes
          • Accessories and consumables
        • Canada Source Outlook (Revenue, USD Million, 2012 - 2022)
          • Mammalian
          • Non-mammalian 
            • Insects
            • Amphibians
        • Canada Type of Cell Line Outlook (Revenue, USD Million, 2012 - 2022)
          • Recombinant cell lines
          • Hybridomas
          • Continuous cell lines
          • Primary cell lines
        • Canada Application Outlook (Revenue, USD Million, 2012 - 2022)
          • Bioproduction
          • Drug discovery
          • Toxicity resting
          • Tissue engineering
          • Research
    • Europe
      • Europe Product Outlook (Revenue, USD Million, 2012 - 2022)
        • Reagents and media
        • Equipment
          • Incubators
          • Centrifuges
          • Bioreactors
          • Storage equipment
          • Microscopes
        • Accessories and consumables
      • Europe Source Outlook (Revenue, USD Million, 2012 - 2022)
        • Mammalian
        • Non-mammalian 
          • Insects
          • Amphibians
      • Europe Type of Cell Line Outlook (Revenue, USD Million, 2012 - 2022)
        • Recombinant cell lines
        • Hybridomas
        • Continuous cell lines
        • Primary cell lines
      • Europe Application Outlook (Revenue, USD Million, 2012 - 2022)
        • Bioproduction
        • Drug discovery
        • Toxicity resting
        • Tissue engineering
        • Research
      • The U.K.
        • U.K. Product Outlook (Revenue, USD Million, 2012 - 2022)
          • Reagents and media
          • Equipment
            • Incubators
            • Centrifuges
            • Bioreactors
            • Storage equipment
            • Microscopes
          • Accessories and consumables
        • The U.K. Source Outlook (Revenue, USD Million, 2012 - 2022)
          • Mammalian
          • Non-mammalian 
            • Insects
            • Amphibians
        • The U.K. Type of Cell Line Outlook (Revenue, USD Million, 2012 - 2022)
          • Recombinant cell lines
          • Hybridomas
          • Continuous cell lines
          • Primary cell lines
        • The U.K. Application Outlook (Revenue, USD Million, 2012 - 2022)
          • Bioproduction
          • Drug discovery
          • Toxicity resting
          • Tissue engineering
          • Research
      • Germany
        • Germany Product Outlook (Revenue, USD Million, 2012 - 2022)
          • Reagents and media
          • Equipment
            • Incubators
            • Centrifuges
            • Bioreactors
            • Storage equipment
            • Microscopes
          • Accessories and consumables
        • Germany Source Outlook (Revenue, USD Million, 2012 - 2022)
          • Mammalian
          • Non-mammalian 
            • Insects
            • Amphibians
        • Germany Type of Cell Line Outlook (Revenue, USD Million, 2012 - 2022)
          • Recombinant cell lines
          • Hybridomas
          • Continuous cell lines
          • Primary cell lines
        • Germany Application Outlook (Revenue, USD Million, 2012 - 2022)
          • Bioproduction
          • Drug discovery
          • Toxicity resting
          • Tissue engineering
          • Research
    • Asia Pacific
      • Asia Pacific Product Outlook (Revenue, USD Million, 2012 - 2022)
        • Reagents and media
        • Equipment
          • Incubators
          • Centrifuges
          • Bioreactors
          • Storage equipment
          • Microscopes
        • Accessories and consumables
      • Asia Pacific Source Outlook (Revenue, USD Million, 2012 - 2022)
        • Mammalian
        • Non-mammalian 
          • Insects
          • Amphibians
      • Asia Pacific Type of Cell Line Outlook (Revenue, USD Million, 2012 - 2022)
        • Recombinant cell lines
        • Hybridomas
        • Continuous cell lines
        • Primary cell lines
      • Asia Pacific Application Outlook (Revenue, USD Million, 2012 - 2022)
        • Bioproduction
        • Drug discovery
        • Toxicity resting
        • Tissue engineering
        • Research
      • Japan
        • Japan Product Outlook (Revenue, USD Million, 2012 - 2022)
          • Reagents and media
          • Equipment
            • Incubators
            • Centrifuges
            • Bioreactors
            • Storage equipment
            • Microscopes
          • Accessories and consumables
        • Japan Source Outlook (Revenue, USD Million, 2012 - 2022)
          • Mammalian
          • Non-mammalian 
            • Insects
            • Amphibians
        • Japan Type of Cell Line Outlook (Revenue, USD Million, 2012 - 2022)
          • Recombinant cell lines
          • Hybridomas
          • Continuous cell lines
          • Primary cell lines
        • Japan Application Outlook (Revenue, USD Million, 2012 - 2022)
          • Bioproduction
          • Drug discovery
          • Toxicity resting
          • Tissue engineering
          • Research
      • China
        • China Product Outlook (Revenue, USD Million, 2012 - 2022)
          • Reagents and media
          • Equipment
            • Incubators
            • Centrifuges
            • Bioreactors
            • Storage equipment
            • Microscopes
          • Accessories and consumables
        • China Source Outlook (Revenue, USD Million, 2012 - 2022)
          • Mammalian
          • Non-mammalian 
            • Insects
            • Amphibians
        • China Type of Cell Line Outlook (Revenue, USD Million, 2012 - 2022)
          • Recombinant cell lines
          • Hybridomas
          • Continuous cell lines
          • Primary cell lines
        • China Application Outlook (Revenue, USD Million, 2012 - 2022)
          • Bioproduction
          • Drug discovery
          • Toxicity resting
          • Tissue engineering
          • Research
      • India
        • India Product Outlook (Revenue, USD Million, 2012 - 2022)
          • Reagents and media
          • Equipment
            • Incubators
            • Centrifuges
            • Bioreactors
            • Storage equipment
            • Microscopes
          • Accessories and consumables
        • India Source Outlook (Revenue, USD Million, 2012 - 2022)
          • Mammalian
          • Non-mammalian 
            • Insects
            • Amphibians
        • India Type of Cell Line Outlook (Revenue, USD Million, 2012 - 2022)
          • Recombinant cell lines
          • Hybridomas
          • Continuous cell lines
          • Primary cell lines
        • India Application Outlook (Revenue, USD Million, 2012 - 2022)
          • Bioproduction
          • Drug discovery
          • Toxicity resting
          • Tissue engineering
          • Research
    • Latin America
      • Latin America Product Outlook (Revenue, USD Million, 2012 - 2022)
        • Reagents and media
        • Equipment
          • Incubators
          • Centrifuges
          • Bioreactors
          • Storage equipment
          • Microscopes
        • Accessories and consumables
      • Latin America Source Outlook (Revenue, USD Million, 2012 - 2022)
        • Mammalian
        • Non-mammalian 
          • Insects
          • Amphibians
      • Latin America Type of Cell Line Outlook (Revenue, USD Million, 2012 - 2022)
        • Recombinant cell lines
        • Hybridomas
        • Continuous cell lines
        • Primary cell lines
      • Latin America Application Outlook (Revenue, USD Million, 2012 - 2022)
        • Bioproduction
        • Drug discovery
        • Toxicity resting
        • Tissue engineering
        • Research
      • Mexico
        • Mexico Product Outlook (Revenue, USD Million, 2012 - 2022)
          • Reagents and media
          • Equipment
            • Incubators
            • Centrifuges
            • Bioreactors
            • Storage equipment
            • Microscopes
          • Accessories and consumables
        • Mexico Source Outlook (Revenue, USD Million, 2012 - 2022)
          • Mammalian
          • Non-mammalian 
            • Insects
            • Amphibians
        • Mexico Type of Cell Line Outlook (Revenue, USD Million, 2012 - 2022)
          • Recombinant cell lines
          • Hybridomas
          • Continuous cell lines
          • Primary cell lines
        • Mexico Application Outlook (Revenue, USD Million, 2012 - 2022)
          • Bioproduction
          • Drug discovery
          • Toxicity resting
          • Tissue engineering
          • Research
      • Brazil
        • Brazil Product Outlook (Revenue, USD Million, 2012 - 2022)
          • Reagents and media
          • Equipment
            • Incubators
            • Centrifuges
            • Bioreactors
            • Storage equipment
            • Microscopes
          • Accessories and consumables
        • Brazil Source Outlook (Revenue, USD Million, 2012 - 2022)
          • Mammalian
          • Non-mammalian 
            • Insects
            • Amphibians
        • Brazil Type of Cell Line Outlook (Revenue, USD Million, 2012 - 2022)
          • Recombinant cell lines
          • Hybridomas
          • Continuous cell lines
          • Primary cell lines
        • Brazil Application Outlook (Revenue, USD Million, 2012 - 2022)
          • Bioproduction
          • Drug discovery
          • Toxicity resting
          • Tissue engineering
          • Research
    • MEA
      • MEA Product Outlook (Revenue, USD Million, 2012 - 2022)
        • Reagents and media
        • Equipment
          • Incubators
          • Centrifuges
          • Bioreactors
          • Storage equipment
          • Microscopes
        • Accessories and consumables
      • MEA Source Outlook (Revenue, USD Million, 2012 - 2022)
        • Mammalian
        • Non-mammalian 
          • Insects
          • Amphibians
      • MEA Type of Cell Line Outlook (Revenue, USD Million, 2012 - 2022)
        • Recombinant cell lines
        • Hybridomas
        • Continuous cell lines
        • Primary cell lines
      • MEA Application Outlook (Revenue, USD Million, 2012 - 2022)
        • Bioproduction
        • Drug discovery
        • Toxicity resting
        • Tissue engineering
        • Research
      • South Africa
        • South Africa Product Outlook (Revenue, USD Million, 2012 - 2022)
          • Reagents and media
          • Equipment
            • Incubators
            • Centrifuges
            • Bioreactors
            • Storage equipment
            • Microscopes
          • Accessories and consumables
        • South Africa Source Outlook (Revenue, USD Million, 2012 - 2022)
          • Mammalian
          • Non-mammalian 
            • Insects
            • Amphibians
        • South Africa Type of Cell Line Outlook (Revenue, USD Million, 2012 - 2022)
          • Recombinant cell lines
          • Hybridomas
          • Continuous cell lines
          • Primary cell lines
        • South Africa Application Outlook (Revenue, USD Million, 2012 - 2022)
          • Bioproduction
          • Drug discovery
          • Toxicity resting
          • Tissue engineering
          • Research

Report content

Qualitative Analysis

  • Industry overview
  • Industry trends
  • Market drivers and restraints
  • Market size
  • Growth prospects
  • Porter’s analysis
  • PESTEL analysis
  • Key market opportunities prioritized
  • Competitive landscape
    • Company overview
    • Financial performance
    • Product benchmarking
    • Latest strategic developments

Quantitative Analysis

  • Market size, estimates, and forecast from 2012 to 2022
  • Market estimates and forecast for product segments up to 2022
  • Regional market size and forecast for product segments up to 2022
  • Market estimates and forecast for application segments up to 2022
  • Regional market size and forecast for application segments up to 2022
  • Company financial performance
What questions do you have? Get quick response from our industry experts. Request a Free Consultation
gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.